Introduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...
Read moreWe look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...
Read moreOur Market Access Analysts discuss the proposed changes to CAR-T reimbursement in the US and conside...
Read moreFrance’s Health Innovation Plan 2030, announced by President Emmanuel Macron back in June 2021, wi...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe report looks at how differences in cancer survival rates between the UK and other countries have...
Read moreThe IPCEI was signed to address the need to equip Europe with a strong, innovative and export-friend...
Read moreAccording to the Department of Health and Social Care (DHSC), the commitments will enable patients t...
Read morePRIME medicines include CAR T-cell therapies, one-time potentially curative gene therapies, rare can...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read more